In This Article:
-
Revenue: $244 million, 10% reported growth, flat organic growth.
-
Adjusted Gross Margin: 46%, up 70 basis points excluding Motion Solutions acquisition impact.
-
Adjusted EBITDA: $57 million, 23% margin, 9% year-over-year growth.
-
Bookings Growth: 13% year-over-year.
-
R&D Expenses: $23 million, 10% of sales.
-
SG&A Expenses: $44 million, 18% of sales.
-
Non-GAAP Tax Rate: 21% for the third quarter, 19% expected for the full year.
-
Adjusted EPS: $0.85, flat year-over-year.
-
Operating Cash Flow: $23 million for the third quarter.
-
Gross Debt Balance: $460 million, gross leverage ratio of 2.3 times.
-
Net Debt: $368 million.
-
Book-to-Bill Ratio: 0.89 overall, 1.4 in minimally invasive surgery business line.
-
Precision Medicine and Manufacturing Sales Decline: 15% year-over-year.
-
Robotics and Automation Revenue Increase: 20% year-over-year.
-
Medical Solutions Revenue Growth: 24% reported, 1% organic decline.
-
Fourth Quarter Revenue Guidance: $237 million to $242 million, 12% to 14% reported growth, 2% to 4% organic growth.
-
Full Year 2024 Revenue Guidance: $948 million to $953 million, 8% reported growth.
-
Adjusted EBITDA Guidance for Q4: $50 million to $52 million.
-
Adjusted EPS Guidance for Q4: $0.70 to $0.74.
Release Date: November 05, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Novanta Inc (NASDAQ:NOVT) delivered strong third-quarter results, reaching the top end of their guidance range.
-
The company reported $244 million in revenue, representing a 10% growth, with adjusted EBITDA growing 9% year-over-year.
-
Bookings grew 13% year-over-year, indicating strong demand for new product launches in 2025.
-
Novanta Inc (NASDAQ:NOVT) is optimistic about returning to organic growth in the fourth quarter of 2024 and expects strong growth in 2025.
-
The company is well-positioned in markets with long-term secular growth trends, such as precision medicine, minimally invasive surgery, and robotics and automation.
Negative Points
-
Fourth-quarter revenue guidance is impacted by the rescheduling of DNA sequencing product shipments and new product launch timing shifts.
-
Short-term timing changes and macroeconomic factors are affecting customer confidence and capital equipment market demand.
-
Adjusted gross margins were down year-over-year due to lower factory utilization and the impact of the Motion Solutions acquisition.
-
The precision medicine and manufacturing segment experienced a 15% sales decline, weaker than prior expectations.
-
The company's book-to-bill ratio was 0.89, indicating a weaker demand environment in life science and advanced industrial applications.